| Followers | 200 |
| Posts | 25596 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Thursday, February 01, 2024 3:02:14 PM
Thanks ExW.
I don’t think that means what people seem to think it means based on what sounds like were superficial reads.
Does sound like a general ballpark and it makes sense if you’re growing a portfolio of potential drugs with great prospects yet unproven, and further the conversation, related to Daiichi to collaborate also has critical substance as well.
But as for buyouts, it’s always about the product, its capability and what the sellers are willing to take for it if they can control the sale and the acquirer doesn’t want the mess of a hostile takeover, which BP typically doesn’t really want with these small drugs with complex issues around transfer.
Interesting but not as dramatic as some make it seem. Reasonable targets for Merck to enunciate.
I don’t think that means what people seem to think it means based on what sounds like were superficial reads.
Does sound like a general ballpark and it makes sense if you’re growing a portfolio of potential drugs with great prospects yet unproven, and further the conversation, related to Daiichi to collaborate also has critical substance as well.
But as for buyouts, it’s always about the product, its capability and what the sellers are willing to take for it if they can control the sale and the acquirer doesn’t want the mess of a hostile takeover, which BP typically doesn’t really want with these small drugs with complex issues around transfer.
Interesting but not as dramatic as some make it seem. Reasonable targets for Merck to enunciate.
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
